SCHEMBL21484640

SCHEMBL21484640

COc1ccc(CN(C(=O)O)c2nc(B3OC(C)(C)C(C)(C)O3)cs2)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
UCHL1 P09936 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
USP2 O75604 1/20 0.38
TSHR P16473 1/20 0.38
TSPO P30536 1/20 0.38
RNF4 P78317 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21505301 0.88 USP30 (0.39) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL21495058 0.81 MEN1 (0.38) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL19031380 0.80 USP30 (0.47) MEN1KMT2AALDH1A1LMNAUCHL1
SCHEMBL21484702 0.78 KMT2A (0.46) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL14718889 0.75 NPC1 (0.34) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL21484642 0.72 ALDH1A1 (0.44) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL21495081 0.71 SCN1A (0.61) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL28521283 0.70 RAB9A (0.35) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL17643639 0.69 USP30 (0.59) MEN1KMT2AALDH1A1UCHL1NPSR1
SCHEMBL6900233 0.68 MAPT (0.35) MEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023239941-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC. (US) 2023-12-14 WO disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556756-B1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2020-10-07 EP disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
WO-2019201867-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed
EP-3556756-A1 SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MEN1 1727/4885KMT2A 805/4885RAB9A 2879/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MEN1 1727/4885KMT2A 805/4885RAB9A 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.